Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 1 3Phase 3 2

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Mastocytosis, Systemic 1Leukemia, Mast-Cell 1Leukemia 1Aggression 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × midostaurin × Clear all
NCT03591510 2026-04-27

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Novartis

Phase 2 Active not recruiting
22 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03280030 2025-03-20

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Novartis

Phase 2 Completed
67 enrolled 21 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01883362 2021-03-17

RADIUS

Novartis

Phase 2 Completed
60 enrolled 17 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡